While the absence of inactivating MH2 germline mutations from this study provides compelling evidence that SMAD3 and SMAD4 mutations are truly rare in breast cancer, this study cannot comprehensively exclude the presence of other mutations since the Mad-Homology 1 (MH1) and the variable linker region were not screened. The gene discussed is SMAD4; the disease is breast cancer.